BACKGROUND: Ischemic stroke remains one of the leading causes of death and disability in the developed world. Despite many promising preclinical results, the only pharmacologic treatments proven effective in improving clinical outcome following ischemic stroke until now are administration of aspirin and acute thrombolysis using tissue-plasminogen activator. OBJECTIVE: To review currently approved pharmacologic therapies as well as promising future treatment strategies for acute ischemic stroke. METHODS: We performed an exhaustive PubMed search for articles published from 1950 through 2009 describing pharmacotherapy of acute ischemic stroke, focusing on agents that are currently in Phase III trials or approved for clinical use. Following this review, we present our interpretation of the existing literature and our vision of the future of pharmacotherapy for ischemic stroke. RESULTS/ CONCLUSIONS: Since the clinical success of the first intravenous thrombolytic, many studies have sought to further characterize the ideal patient population and to extend the therapeutic time window for pharmacologic thrombolysis. Additionally, despite the many failures of neuroprotective trials, several promising agents are currently undergoing Phase III investigation. With the advent of interventional techniques enabling local delivery of therapeutics into the region of the thrombus, the future of pharmacotherapy for ischemic stroke will probably include a combination of interventional techniques and pharmacotherapy.
BACKGROUND:Ischemic stroke remains one of the leading causes of death and disability in the developed world. Despite many promising preclinical results, the only pharmacologic treatments proven effective in improving clinical outcome following ischemic stroke until now are administration of aspirin and acute thrombolysis using tissue-plasminogen activator. OBJECTIVE: To review currently approved pharmacologic therapies as well as promising future treatment strategies for acute ischemic stroke. METHODS: We performed an exhaustive PubMed search for articles published from 1950 through 2009 describing pharmacotherapy of acute ischemic stroke, focusing on agents that are currently in Phase III trials or approved for clinical use. Following this review, we present our interpretation of the existing literature and our vision of the future of pharmacotherapy for ischemic stroke. RESULTS/ CONCLUSIONS: Since the clinical success of the first intravenous thrombolytic, many studies have sought to further characterize the ideal patient population and to extend the therapeutic time window for pharmacologic thrombolysis. Additionally, despite the many failures of neuroprotective trials, several promising agents are currently undergoing Phase III investigation. With the advent of interventional techniques enabling local delivery of therapeutics into the region of the thrombus, the future of pharmacotherapy for ischemic stroke will probably include a combination of interventional techniques and pharmacotherapy.
Authors: Andrew F Ducruet; William J Mack; J Mocco; Daniel J Hoh; Alexander L Coon; Anthony L D'Ambrosio; Christopher J Winfree; David J Pinsky; E Sander Connolly Journal: Transl Stroke Res Date: 2011-05-17 Impact factor: 6.829
Authors: William A Kofke; Yue Ren; John G Augoustides; Hongzhe Li; Katherine Nathanson; Robert Siman; Qing Cheng Meng; Weiming Bu; Sukanya Yandrawatthana; Guy Kositratna; Cecilia Kim; Joseph E Bavaria Journal: Front Neurol Date: 2018-06-26 Impact factor: 4.003